Longeveron (LGVN) Depreciation & Amortization (CF) (2020 - 2026)

Longeveron (LGVN) recorded quarterly Depreciation & Amortization (CF) of $252000.0 in Q1 2026, down 9.35% quarter-over-quarter from $278000.0 in Q4 2025, and down 40.14% on a YoY basis from $421000.0 in Q1 2025.

Longeveron (LGVN) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

Longeveron's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $252000.0 for Q1 2026.

  • In Q1 2026, Depreciation & Amortization (CF) fell 40.14% year-over-year to $252000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 6.21% YoY), while the FY2025 annual figure was $1.2 million, up 27.97% from the prior year.
  • Depreciation & Amortization (CF) was $252000.0 for Q1 2026 at Longeveron, down from $278000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $421000.0 in Q1 2025 to a low of $188000.0 in Q1 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $251470.6 across 5 years, with a median of $240000.0 in 2022.
  • The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) jumped 67.06% in 2025, then tumbled 40.14% in 2026.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $236000.0 in 2022, then changed by 0.0% to $236000.0 in 2023, then grew by 2.54% to $242000.0 in 2024, then increased by 14.88% to $278000.0 in 2025, then declined by 9.35% to $252000.0 in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $252000.0 (Q1 2026), $278000.0 (Q4 2025), and $264000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 1,395.22
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1,330.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 55.90 Mn
9 Abivax 91.96 Bn 91.96 Bn - 429,663.65
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00 252,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 252,000.00
Mar 31, 2026 252,000.00
Dec 31, 2025 278,000.00
Dec 31, 2025 278,000.00
Sep 30, 2025 264,000.00
Sep 30, 2025 264,000.00
Jun 30, 2025 263,000.00
Jun 30, 2025 263,000.00
Mar 31, 2025 421,000.00
Mar 31, 2025 421,000.00
Dec 31, 2024 242,000.00
Dec 31, 2024 242,000.00
Sep 30, 2024 235,000.00
Sep 30, 2024 235,000.00
Jun 30, 2024 229,000.00
Jun 30, 2024 229,000.00
Mar 31, 2024 252,000.00
Mar 31, 2024 252,000.00
Dec 31, 2023 236,000.00
Dec 31, 2023 236,000.00